Treatment-related adverse events occurred in 36 older patients receiving saxagliptin versus 32 receiving placebo ( incidence rate 34.1 versus 27.1 per 100 person-years ) and in 150 younger patients in both treatment groups ( incidence rate 24.0 versus 27.8 per 100 person-years ) .